Clinical Trials MELD-ATG

ATG, given once in a two days infusion regimen, is a drug recently shown to be able to keep the balance between attacking and regulating cells within the immune system, and thereby helping to preserve insulin secretion.

The drug ATG (Anti Thymocyte Globulin) provided by our partner Sanofi, will be tested over 12 months in children to adults (5 to 25 years, n=114). ATG, given once in a two days infusion regimen, is a drug recently shown to be able to keep the balance between attacking and regulating cells within the immune system, and thereby helping to preserve insulin secretion. Defining the minimal effective dose of ATG treatment is one aim of the study.

For more Information

Please download the PDF below:

Other Innodia Trials:

How to Participate:

Is your country not available?
Send us a mail so we can contact you when the trial starts close to you!